Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shunta Nagashima

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Current Drug Targets|January 14, 2016
The Hippo Pathway as Drug Targets in Cancer Therapy and Regenerative MedicineShunta Nagashima, Yijun Bao, Yutaka Hata
Journal of Biochemistry|February 1, 2015
MAGI2/S-SCAM outside brainShunta Nagashima, Manami Kodaka, Hiroaki Iwasa, et al.
Cancer Science|February 1, 2022
Protein kinase Cα activation switches YAP1 from TEAD-mediated signaling to p73-mediated signalingCaleb Kwame Sinclear, Junichi Maruyama, Shunta Nagashima, et al.
Cancer Science|March 25, 2016
Validation of chemical compound library screening for transcriptional co-activator with PDZ-binding motif inhibitors using GFP-fused transcriptional co-activator with PDZ-binding motifShunta Nagashima, Junichi Maruyama, Shodai Kawano, et al.
Journal of Biochemistry|May 17, 2015
A cell-based screening for TAZ activators identifies ethacridine, a widely used antiseptic and abortifacient, as a compound that promotes dephosphorylation of TAZ and inhibits adipogenesis in C3H10T1/2 cellsShodai Kawano, Junichi Maruyama, Shunta Nagashima, et al.
The Journal of Biological Chemistry|May 22, 2021
CSE1L promotes nuclear accumulation of transcriptional coactivator TAZ and enhances invasiveness of human cancer cellsShunta Nagashima, Junichi Maruyama, Kaori Honda, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Current Drug Targets|January 14, 2016
The Hippo Pathway as Drug Targets in Cancer Therapy and Regenerative MedicineShunta Nagashima, Yijun Bao, Yutaka Hata
Journal of Biochemistry|February 1, 2015
MAGI2/S-SCAM outside brainShunta Nagashima, Manami Kodaka, Hiroaki Iwasa, et al.
Cancer Science|February 1, 2022
Protein kinase Cα activation switches YAP1 from TEAD-mediated signaling to p73-mediated signalingCaleb Kwame Sinclear, Junichi Maruyama, Shunta Nagashima, et al.
Cancer Science|March 25, 2016
Validation of chemical compound library screening for transcriptional co-activator with PDZ-binding motif inhibitors using GFP-fused transcriptional co-activator with PDZ-binding motifShunta Nagashima, Junichi Maruyama, Shodai Kawano, et al.
Journal of Biochemistry|May 17, 2015
A cell-based screening for TAZ activators identifies ethacridine, a widely used antiseptic and abortifacient, as a compound that promotes dephosphorylation of TAZ and inhibits adipogenesis in C3H10T1/2 cellsShodai Kawano, Junichi Maruyama, Shunta Nagashima, et al.
The Journal of Biological Chemistry|May 22, 2021
CSE1L promotes nuclear accumulation of transcriptional coactivator TAZ and enhances invasiveness of human cancer cellsShunta Nagashima, Junichi Maruyama, Kaori Honda, et al.
Pageof 1